Giving tranexamic acid to reduce surgical bleeding in sub-Saharan Africa: An economic evaluation

Cost Effectiveness and Resource Allocation

Volumn 8, Issue , 2010, Pages

  Guerriero, Carla ^a   Cairns, John ^a   Jayaraman, Sudha ^b   Roberts, Ian ^a   Perel, Pablo ^a   Shakur, Haleema ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANEXAMIC ACID;

ARTICLE; BLEEDING; BLOOD DONOR; BLOOD TRANSFUSION; BOTSWANA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMIC EVALUATION; ELECTIVE SURGERY; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; KENYA; MAJOR CLINICAL STUDY; MORTALITY; RISK REDUCTION; SOUTH AFRICA; TANZANIA;

EID: 77949560850     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-8-1     Document Type: Article

References (42)

1. Allain JP, Owusu-Ofori S, Bates I. Blood Transfusion in Sub-Saharan Africa. Transfusion Alternatives in Transfusion Medicine 2004, 6(1):16-23.
2. Tapko JB, Sam O, Diarra-Nama AJ. Status of blood safety in the WHO African Region: Report of the 2004 Survey. WHO Regional Office for Africa 2004,
3. WHO Global Database on Blood Safety. Summary Report 1998-1999 2004, WHO.
4. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007, CD001886.
5. CRASH 2 trial (Clinical Randomization of an Antyfibrinolitic in Significant Hemorrage) and Woman trial (World Maternal Antifybrinolitic Trial). , http://www.trialscoordinatingcentre.lshtm.ac.uk/
6. Progress toward strengthening blood transfusion services--14 countries, 2003-2007. MMWR Morb Mortal Wkly Rep 2008, 57:1273-1277.
7. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000, 9:235-251. 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O, 10790702.
8. Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess 2006, 10. iii-iv, ix-x, 1-210.
9. WHO Strategies of safe blood transfusions. World Health Day 2000, WHO.
10. The President Emergency Plan for AIDS Relief Report on Blood Safety and HIV/AIDS. 2006, The President Emergency Plan for AIDS Relief.
11. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews 2007, 4.
12. WHOSIS Mortality and burden of disease. 2008, WHOSIS.
13. Bates I, Chapotera GK, McKew S, Broek N. Maternal mortality in sub-Saharan Africa: the contribution of ineffective blood transfusion services. BJOG 2008, 115:1331-1339. 10.1111/j.1471-0528.2008.01866.x, 18823485.
14. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002, 42:812-818. 10.1046/j.1537-2995.2002.00123.x, 12375651.
15. Jarayaman S, Chalabi Z, Perel P, Guerriero C, Roberts I. The risk of transfusion-transmitted infections in sub-Saharan Africa. Transfusion
16. Remis R, . the Hepatitis C Working Group Estimating the number of blood transfusions recipients infected by Hepatitis C virus in Canada 1960-85 and 1990-92. 1998, the Hepatitis C Working Group.
17. Bates I, Manyasi G, Medina Lara A. Reducing replacement donors in Sub-Saharan Africa: challenges and affordability. Transfus Med 2007, 17:434-442.
18. Bureau of National Statistics United States Department of Labor. Historical Consumer Price Index U.S. city average 2009, (Accessed 30 January 2009), Bureau of National Statistics., http://www.bls.gov/cpi/#tables
19. Jacobs B, Mercer A. Feasibility of hospital-based blood banking: a Tanzanian case study. Health Policy Plan 1999, 14:354-362. 10.1093/heapol/14.4.354, 10787651.
20. Casati V, Guzzon D, Oppizzi M, Cossolini M, Torri G, Calori G, Alfieri O. Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery. Ann Thorac Surg 1999, 68:2252-2256. discussion 2256-2257, 10.1016/S0003-4975(99)00866-8, 10617012.
21. Benoni G, Fredin H, Knebel R, Nilsson P. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. Acta Orthop Scand 2001, 72:442-448.
22. Lozano M, Basora M, Peidro L, Merino I, Segur JM, Pereira A, Salazar F, Cid J, Lozano L, Mazzara R, Macule F. Effectiveness and safety of tranexamic acid administration during total knee arthroplasty. Vox Sang 2008, 95:39-44. 10.1111/j.1423-0410.2008.01045.x, 18363576.
23. Nuttall GA, Gutierrez MC, Dewey JD, Johnson ME, Oyen LJ, Hanson AC, Oliver WC. A preliminary study of a new tranexamic acid dosing schedule for cardiac surgery. J Cardiothorac Vasc Anesth 2008, 22:230-235. 10.1053/j.jvca.2007.12.016, 18375325.
24. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of tranexamic acid. Anesthesiology 1995, 82:383-392. 10.1097/00000542-199502000-00009, 7856897.
25. CRASH 2 trial (Clinical Randomization of an Antyfibrinolitic in Significant Hemorrage) and Woman trial (World Maternal Antifybrinolitic Trial). 2009,
26. Joint Formulary Committee British National Formulary London. 2007, 65. Joint Formulary Committee.
27. Organization for Economic Co-operation and Development (OECD) Purchaser Power Parities and Exchange rates. Organization for Economic Co-operation and Development (OECD)., http://stats.oecd.org/wbos/Index.aspx?datasetcode=SNA_TABLE4
28. Proposal for the Inclusion of Tranexamic acid (anti-fibrinolytic lysine analogue) in the WHO list of essential medicines. Draft Report. , http://www.who.int/selection_medicines/committees/expert/17/application/ TRANEXAMIC_ACID.pdf
29. Eaton MP. Antifibrinolytic therapy in surgery for congenital heart disease. Anesth Analg 2008, 106:1087-1100. 10.1213/ane.0b013e3181679555, 18349177.
30. National Commissioning Group 2008/2009 Cost Pressures, Development and Proposals and Cost Reduction Programmes for Blood Components Products. (NHS Blood and Transplant ed) 2009, National Commissioning Group.
31. Briggs A, Claxton K, Sculpter M. Decision Modelling for Health Economic Evaluation. Oxford Handbook in Economic Evaluation 2008,
32. Commission on Macroeconomics and Health Macroeconomics and health: investing in health for economic development. 2001, Geneva: World Health Organization, Commission on Macroeconomics and Health.
33. The World. Bank Annual report: Income per capita 2007. 2008,
34. Hensher M, Jefferys E. Financing blood transfusion services in sub-Saharan Africa: a role for user fees?. Health Policy Plan 2000, 15:287-295. 10.1093/heapol/15.3.287, 11012403.
35. Mensah GA. Ischaemic heart disease in Africa. Heart 2008, 94:836-843. 10.1136/hrt.2007.136523, 18552223.
36. McGill P. Rheumatoid arthritis in sub-Saharan Africa. Ann Rheum Dis 1991, 50:965-966. 10.1136/ard.50.12.965, 1004595, 1768173.
37. Ozgediz D, Riviello R. The "other" neglected diseases in global public health: surgical conditions in sub-Saharan Africa. PLoS Med 2008, 5:e121. 10.1371/journal.pmed.0050121, 2408612,2408612, 18532875.
38. A crucial role for surgery in reaching the UN millennium development goals. PLoS Med 2008, 5:e182. 10.1371/journal.pmed.0050182, 2522259, 18752346.
39. Mwangi JW. Viral markers in a blood donor population. East Afr Med J 1999, 76:35-37.
40. Hasegawa I, Tanaka Y, Kurbanov F, Yoshihara N, El-Gohary A, Lyamuya E, Matee M, Magessa P, Fujiwara K, Ozasa A, et al. Molecular epidemiology of hepatitis B virus in the United Republic of Tanzania. J Med Virol 2006, 78:1035-1042. 10.1002/jmv.20659, 16789015.
41. Matee MI, Magesa PM, Lyamuya EF. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 2006, 6:21. 10.1186/1471-2458-6-21, 1373616, 16445860.
42. Croce F, Fedeli P, Dahoma M, Deho L, Ramsan M, Adorni F, Corvasce S, Galli M. Risk factors for HIV/AIDS in a low HIV prevalence site of sub-Saharan Africa. Trop Med Int Health 2007, 12:1011-1017.